Find out why Entyvio (Vedolizumab) is so hard to find in 2026. Learn about supply issues, specialty pharmacy limits, and what you can do to get your medication.
If you or someone you love depends on Entyvio (Vedolizumab) to manage Crohn's disease or ulcerative colitis, you already know how stressful it can be when your pharmacy can't fill your prescription. You're not alone — and you're not imagining the problem.
Entyvio is one of the most prescribed biologics for inflammatory bowel disease (IBD), and its popularity has only grown since its FDA approval in 2014. But that growing demand, combined with the realities of specialty drug manufacturing and distribution, means that finding Entyvio in stock isn't always straightforward.
In this article, we'll break down exactly why Entyvio can be so hard to find in 2026, and — more importantly — what you can do about it.
Entyvio is the brand name for Vedolizumab, a biologic medication made by Takeda Pharmaceuticals. It belongs to a class of drugs called integrin receptor antagonists (also known as selective immunosuppressants).
Unlike many other biologics that suppress the immune system throughout the entire body, Entyvio works specifically in the gut. It blocks a protein called integrin α4β7 on certain immune cells, preventing them from migrating to the lining of the gastrointestinal tract and causing inflammation.
Entyvio is FDA-approved to treat:
It's available as an IV infusion (300 mg, given at an infusion center) and as a subcutaneous injection using the Entyvio Pen (108 mg, self-administered at home). For more details on how the drug works, check out our guide on how Entyvio works.
Unlike a standard prescription you'd pick up at your local CVS or Walgreens, Entyvio is a specialty medication. That means it's distributed through specialty pharmacies and infusion centers, not your typical retail pharmacy.
Specialty pharmacies carry a limited inventory of high-cost biologics, and they often need to order Entyvio specifically for each patient. If there's a delay in the supply chain — even a small one — it can mean days or weeks of waiting.
For the IV formulation, you also need to schedule time at an infusion center, which adds another layer of logistics. Infusion centers may have limited appointment availability, especially in high-demand areas.
Entyvio is made exclusively by Takeda Pharmaceuticals. As of 2026, there are no FDA-approved biosimilars or generic versions of Vedolizumab. While companies like Alvotech and Polpharma are developing biosimilar candidates, those aren't expected to reach the market until 2028 at the earliest.
When a single company is responsible for the entire global supply of a medication — one that generated approximately $6.4 billion in worldwide revenue in 2025 — any manufacturing hiccup, quality control issue, or raw material shortage can ripple through the entire supply chain.
The number of people diagnosed with IBD continues to rise. According to the CDC, an estimated 3 million adults in the U.S. have been diagnosed with IBD, and many of them require biologic therapy.
Entyvio's gut-selective mechanism makes it an attractive option for patients and doctors who want effective treatment with fewer systemic side effects. As more patients are prescribed Entyvio — for both ulcerative colitis and Crohn's disease — demand continues to outpace what the supply chain can comfortably handle.
Even when Entyvio is physically available, insurance hurdles can make it feel impossible to access. Most insurance plans require prior authorization before they'll cover Entyvio, and many require step therapy — meaning you have to try (and fail on) cheaper medications first.
These administrative processes can take days to weeks, during which time your prescription sits unfilled. If your approval lapses or your insurance changes, you may need to start the process all over again.
For tips on navigating insurance requirements, see our post on how to save money on Entyvio.
The good news is that there are real, practical steps you can take to improve your chances of getting Entyvio when you need it.
Medfinder lets you search for pharmacies and infusion centers that have Entyvio in stock right now. Instead of calling around to dozens of specialty pharmacies, you can check availability in seconds.
If one formulation is unavailable, ask your doctor about switching between IV and subcutaneous Entyvio. The Entyvio Pen (108 mg SC) is used for maintenance therapy and can be self-administered at home, which may be easier to obtain through a specialty pharmacy that ships directly to you.
Your gastroenterologist's office likely has relationships with specialty pharmacies and infusion centers. They may know which locations have stock or can expedite orders. Don't hesitate to ask them for help.
If you're on a regular infusion schedule (every 8 weeks for IV, every 2 weeks for SC), try to coordinate your next refill or appointment well in advance. Don't wait until your last dose to start the process.
Takeda's EntyvioConnect program (1-844-368-9846) offers not just copay assistance but also help coordinating your treatment. They can assist with finding infusion centers and navigating supply issues.
Finding Entyvio in 2026 can be frustrating, but understanding why the shortage happens puts you in a better position to navigate it. Between specialty distribution channels, a single manufacturer, rising demand, and insurance barriers, there are multiple factors working against easy access.
But you have options. Tools like Medfinder can help you find Entyvio in stock near you, and programs like EntyvioConnect can ease the financial and logistical burden.
For more information, explore our related guides:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
